MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS) today announced that it has received a $140 million milestone payment from KV Pharmaceutical (“KV”) pursuant to the previously announced transfer of exclusive rights and assets related to Evamist. Under the terms of the transfer, VIVUS received an upfront payment of $10 million upon the May 15, 2007 closing. VIVUS became eligible for an additional payment following the approval by the United States Food and Drug Administration on July 27, 2007.
